This “Necrotizing Enterocolitis - Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Necrotizing Enterocolitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Necrotizing enterocolitis (NEC), which typically occurs in the second to third week of life in premature, formula-fed infants, is characterized by variable damage to the intestinal tract, ranging from mucosal injury to full-thickness necrosis and perforation. In severe cases of NEC, a hole may form in the wall of the intestine. If this occurs, the bacteria normally found inside the intestine can leak into the abdomen and cause widespread infection. This is considered a medical emergency.
"Necrotizing Enterocolitis - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Necrotizing Enterocolitis pipeline landscape is provided which includes the disease overview and Necrotizing Enterocolitis treatment guidelines. The assessment part of the report embraces, in depth Necrotizing Enterocolitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Necrotizing Enterocolitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
This segment of the Necrotizing Enterocolitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
There are approx. 4+ key companies which are developing the therapies for Necrotizing Enterocolitis. The companies which have their Necrotizing Enterocolitis drug candidates in the most advanced stage, i.e. phase III include, Infant Bacterial Therapeutics Biopharma.
Route of Administration
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Necrotizing Enterocolitis therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Necrotizing Enterocolitis drugs.
Geography Covered
- Global coverage
Necrotizing Enterocolitis Understanding
Necrotizing Enterocolitis: Overview
Necrotizing enterocolitis (NEC), which typically occurs in the second to third week of life in premature, formula-fed infants, is characterized by variable damage to the intestinal tract, ranging from mucosal injury to full-thickness necrosis and perforation. In severe cases of NEC, a hole may form in the wall of the intestine. If this occurs, the bacteria normally found inside the intestine can leak into the abdomen and cause widespread infection. This is considered a medical emergency.
"Necrotizing Enterocolitis - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Necrotizing Enterocolitis pipeline landscape is provided which includes the disease overview and Necrotizing Enterocolitis treatment guidelines. The assessment part of the report embraces, in depth Necrotizing Enterocolitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Necrotizing Enterocolitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Necrotizing Enterocolitis R&D. The therapies under development are focused on novel approaches to treat/improve Necrotizing Enterocolitis.
Necrotizing Enterocolitis Emerging Drugs Chapters
This segment of the Necrotizing Enterocolitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Necrotizing Enterocolitis Emerging Drugs
- IBP-9414: Infant Bacterial Therapeutics
- STP-206: Leadiant Biosciences
Necrotizing Enterocolitis: Therapeutic Assessment
This segment of the report provides insights about the different Necrotizing Enterocolitis drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Necrotizing Enterocolitis
There are approx. 4+ key companies which are developing the therapies for Necrotizing Enterocolitis. The companies which have their Necrotizing Enterocolitis drug candidates in the most advanced stage, i.e. phase III include, Infant Bacterial Therapeutics Biopharma.
The report covers around 4+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
Necrotizing Enterocolitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Necrotizing Enterocolitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Necrotizing Enterocolitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Necrotizing Enterocolitis drugs.
Necrotizing Enterocolitis Report Insights
- Necrotizing Enterocolitis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Necrotizing Enterocolitis Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Necrotizing Enterocolitis drugs?
- How many Necrotizing Enterocolitis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Necrotizing Enterocolitis?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Necrotizing Enterocolitis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Necrotizing Enterocolitis and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Infant Bacterial Therapeutics
- Leadiant Biosciences
- Noveome
Key Products
- IBP-9414
- STP-206
- ST 266
Table of Contents
IntroductionExecutive Summary
Necrotizing Enterocolitis: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Necrotizing Enterocolitis - Analytical Perspective
In-depth Commercial Assessment
- Necrotizing Enterocolitis companies' collaborations, Licensing, Acquisition - Deal Value Trends
Necrotizing Enterocolitis Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
- Comparative Analysis
IBP-9414: Infant Bacterial Therapeutics
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
STP-206: Leadiant Biosciences
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Necrotizing Enterocolitis Key Companies
Necrotizing Enterocolitis Key Products
Necrotizing Enterocolitis - Unmet Needs
Necrotizing Enterocolitis - Market Drivers and Barriers
Necrotizing Enterocolitis - Future Perspectives and Conclusion
Necrotizing Enterocolitis Analyst Views
Necrotizing Enterocolitis Key Companies
AppendixList of Tables
Table 1 Total Products for Necrotizing Enterocolitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Necrotizing Enterocolitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Infant Bacterial Therapeutics
- Leadiant Biosciences
- Noveome
